Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine

被引：6

作者：

de Maat, MMR

Beijnen, JH

Schellens, JHM

Mulder, JW

机构：

[1] Slotervaart Hosp, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands

[2] Slotervaart Hosp, Dept Internal Med, NL-1066 EC Amsterdam, Netherlands

[3] Univ Utrecht, Fac Pharmaceut Sci, Utrecht, Netherlands

[4] Antoni Van Leeuwenhoek Hosp, Dept Internal Med, Amsterdam, Netherlands

来源：

JOURNAL OF INFECTION | 2005年 / 50卷 / 03期

关键词：

D O I：

10.1016/j.jinf.2004.02.011

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

[No abstract available]

引用

页码：262 / 264

页数：3

共 12 条

[1] CLARITHROMYCIN-INDUCED HEPATOTOXICITY [J].

BROWN, BA ;

WALLACE, RJ ;

GRIFFITH, DE ;

GIRARD, W .

CLINICAL INFECTIOUS DISEASES, 1995, 20 (04) :1073-1074

[2] A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome [J].

Carr, A ;

Miller, J ;

Law, M ;

Cooper, DA .

AIDS, 2000, 14 (03) :F25-F32

[3]

de Requena DG, 2002, AIDS, V16, P290, DOI 10.1097/00002030-200201250-00020

[4] Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy [J].

Martínez, E ;

Blanco, JL ;

Arnaiz, JA ;

Pérez-Cuevas, JB ;

Mocroft, A ;

Cruceta, A ;

Marcos, MA ;

Milinkovic, A ;

García-Viejo, MA ;

Mallolas, J ;

Carné, X ;

Phillips, A ;

Gatell, JM .

AIDS, 2001, 15 (10) :1261-1268

[5] Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases [J].

Miller, KD ;

Cameron, M ;

Wood, LV ;

Dalakas, MC ;

Kovacs, JA .

ANNALS OF INTERNAL MEDICINE, 2000, 133 (03) :192-196

[6] A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients - The INCAS trial [J].

Montaner, JSG ;

Reiss, P ;

Cooper, D ;

Vella, S ;

Harris, M ;

Conway, B ;

Wainberg, MA ;

Smith, D ;

Robinson, P ;

Hall, D ;

Myers, M ;

Lange, JMA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (12) :930-937

[7]

Murphy RL, 1996, EXPERT OPIN INV DRUG, V5, P1183

[8] A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].

NARANJO, CA ;

BUSTO, U ;

SELLERS, EM ;

SANDOR, P ;

RUIZ, I ;

ROBERTS, EA ;

JANECEK, E ;

DOMECQ, C ;

GREENBLATT, DJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245

[9]

ROBINSON P, 1999, 6 C RETR OPP INF CHI

[10] The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals [J].

van Heeswijk, RPG ;

Veldkamp, AI ;

Mulder, JW ;

Meenhorst, PL ;

Wit, FWNM ;

Lange, JMA ;

Danner, SA ;

Foudraine, NA ;

Kwakkelstein, MO ;

Reiss, P ;

Beijnen, JH ;

Hoetelmans, RMW .

AIDS, 2000, 14 (08) :F77-F82

← 1 2 →